Study Graphic

The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug being studied to treat people with moderate to severe atopic dermatitis (AD). AD is a form of eczema (itchy, inflamed skin rash). Single doses of the study drug up to 800mg and multiple doses up to 400mg a day have been given to healthy participants. These doses were generally safe and well tolerated. The dose of study drug in this study will be 200 mg. Study drug will be given as tablets, which you will swallow.

You may be eligible if:

  • You are a healthy male or female 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Study number: B7451032

Be compensated for your time:

The study has two parts (Part A and Part B)

Part A & Part B: You will be paid will be up to $3,400.00 for completion of the study

This study involves: 

Part A & Part B:

You will be in this study up to about 46 days. This does not include the time between screening and dosing, which can be up to 28 days. 

  • 4 dosing periods (during 1 continuous admission)
  • 12 overnight stays
  • 1 follow-up phone call between 28 and 35 days after the last dose There will be at least 3 days between each dose of study drug.

There will be at least 3 days between each dose of study drug.

Please review the informed consent document: B7451032 ICD v 10 OCT 2019

Please review more information about the study: B7451032 Guidelines and Restrictions v 04 Oct 2019